Title
Category
Credits
Event date
Cost
  • Antipsychotics
  • Schizophrenia/ Schizoaffective Disorders
  • Side Effects
  • Treatment Resistance
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Two experts offer a refresher on predictors and identification of treatment-resistant schizophrenia. Drs Correll and Howes also review therapeutic strategies.
  • Adherence
  • Antipsychotics
  • Cognition
  • Neuropsychiatric Disorders
  • Patient/Physician Communication
  • Psychopharmacology
  • Psychotic Disorders
  • Schizophrenia/ Schizoaffective Disorders
  • Sexual Dysfunction
  • Side Effects
  • Veterans and Military Issues
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Side effects from medication have the greatest impact on adherence for patients with Schizophrenia. They lower quality of life, daily functioning, and satisfaction.
  • Adherence
  • Antipsychotics
  • Cognition
  • Neuropsychiatric Disorders
  • Patient/Physician Communication
  • Psychopharmacology
  • Psychotic Disorders
  • Schizophrenia/ Schizoaffective Disorders
  • Sexual Dysfunction
  • Side Effects
  • Veterans and Military Issues
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Schizophrenia affects 1% of the world’s population largely during a patient’s most productive years. Multiple treatments are available, however many gaps to recovery exist. Learn from experts diagnostic criteria for and defining recovery in schizophrenia.
  • Adherence
  • Antipsychotics
  • Cognition
  • Neuropsychiatric Disorders
  • Patient/Physician Communication
  • Psychopharmacology
  • Psychotic Disorders
  • Schizophrenia/ Schizoaffective Disorders
  • Sexual Dysfunction
  • Side Effects
  • Veterans and Military Issues
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Negative symptoms contribute to poor functional outcomes in schizophrenia. Evaluating different symptom domains and understanding the disorder’s reward circuitry can help with intervention and patients’ leading more fulfilling lives.
  • Adherence
  • Antipsychotics
  • Cognition
  • Neuropsychiatric Disorders
  • Patient/Physician Communication
  • Psychopharmacology
  • Psychotic Disorders
  • Schizophrenia/ Schizoaffective Disorders
  • Sexual Dysfunction
  • Side Effects
  • Veterans and Military Issues
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Balancing symptoms and side effects is difficult when treating patients with schizophrenia. New approaches to treatment and new therapies in the pipeline offer hope for this difficult-to-treat mental health disorder.
  • Bipolar Disorder
  • Bipolar Depression
  • Depression
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Drs Goldberg, Swartz, and DelBello discuss the spectrum of bipolar disorder, from major depressive disorder to bipolar I, and assessment strategies for establishing accurate diagnoses, including age, gender, signs and symptoms, and comorbidities to facilitate appropriate treatments and improve patient outcomes.
  • Bipolar Disorder
  • Bipolar Depression
  • Depression
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
As novel agents join the treatment landscape for bipolar I and bipolar II disorder and new data emerge on existing therapeutics, clinicians need education on the latest evidence of the safety and efficacy profiles of existing and emerging treatments for bipolar I and bipolar II disorder. Join Drs Goldberg, DelBello, and Swartz in examining how to integrate this information into clinical practice and provide efficacious and tolerable treatment for patients with bipolar I and bipolar II disorder.
  • Bipolar Disorder
  • Bipolar Depression
  • Depression
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Treating bipolar I and bipolar II depression is not one-size-fits-all. Learn from field experts about practice guidelines, novel agents, and approaches to developing personalized treatment plans for patients with bipolar depression type I and type II.
  • Bipolar Disorder
  • Bipolar Depression
  • Depression
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Dr Goldberg describes the role of the clinician as that of a travel agent, asking the patient, “Where do you want to go; what do you want it to be like there; how do you want to get there;” etc, then providing the patient with the related evidence-supported information. Learn how to become your patients’ travel agent for their journey through optimizing treatment strategies for type I and type II bipolar disorder.
  • Bipolar Disorder
  • Bipolar Depression
  • Depression
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Adopting consensus guidelines while applying new evidence on the latest treatment options can often be a matter of balancing risks, benefits, and tolerability when addressing acute episodes in bipolar I disorder. Sit in on the discussion between three experts as they discuss guideline-directed treatment strategies that address manic and mixed episodes in patients with bipolar I disorder, and listen to one patient’s journey to hope and recovery.

Pages